npj Vaccines (Jan 2024)

A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation

  • Akshay Binayke,
  • Aymaan Zaheer,
  • Siddhesh Vishwakarma,
  • Savita Singh,
  • Priyanka Sharma,
  • Rucha Chandwaskar,
  • Mudita Gosain,
  • Sreevatsan Raghavan,
  • Deepika Rathna Murugesan,
  • Pallavi Kshetrapal,
  • Ramachandran Thiruvengadam,
  • Shinjini Bhatnagar,
  • Anil Kumar Pandey,
  • Pramod Kumar Garg,
  • Amit Awasthi

DOI
https://doi.org/10.1038/s41541-023-00794-9
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Measuring SARS-CoV-2-specific T cell responses is crucial to understanding an individual’s immunity to COVID-19. However, high inter- and intra-assay variability make it difficult to define T cells as a correlate of protection against COVID-19. To address this, we performed systematic review and meta-analysis of 495 datasets from 94 original articles evaluating SARS-CoV-2-specific T cell responses using three assays – Activation Induced Marker (AIM), Intracellular Cytokine Staining (ICS), and Enzyme-Linked Immunospot (ELISPOT), and defined each assay’s quantitative range. We validated these ranges using samples from 193 SARS-CoV-2-exposed individuals. Although IFNγ ELISPOT was the preferred assay, our experimental validation suggested that it under-represented the SARS-CoV-2-specific T cell repertoire. Our data indicate that a combination of AIM and ICS or FluoroSpot assay would better represent the frequency, polyfunctionality, and compartmentalization of the antigen-specific T cell responses. Taken together, our results contribute to defining the ranges of antigen-specific T cell assays and propose a choice of assay that can be employed to better understand the cellular immune response against viral diseases.